Article
The unexpected move by Advanced Medical Optics Inc. (AMO) to acquire VISX Inc. in a $1.27 billion cash and stock deal caught Wall Street-and many in the ophthalmic industry-by complete surprise.
Understanding cerebral/cortical visual impairment: New insights and advances in diagnosis
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
Integrating imaging modalities for early detection of key microscopic abnormalities in diabetic retinopathy
Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD
Adverum Biotechnologies announces topline 52-week results from LUNA Phase 2 trial and 4-year OPTIC results
USC researchers receive $6 million CIRM grant to advance novel dry AMD therapy